Phase 2
N=103
A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib
ALK-positive Advanced NSCLC
Bottom Line
View on ClinicalTrials.gov: NCT03535740 ↗Enrolled (actual)
103
Serious AEs
44.0%
Results posted
Oct 2021
Primary outcome: Primary: Confirmed Objective Response Rate (ORR) Using RECIST v1.1 as Assessed by the Independent Review Committee (IRC) — 26.2 percentage of participants — p=0.0763
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Brigatinib (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Ariad Pharmaceuticals
- Primary completion
- Sep 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Confirmed Objective Response Rate (ORR) Using RECIST v1.1 as Assessed by the Independent Review Committee (IRC) |
26.2 | 0.0763 |
| SECONDARY Confirmed ORR Using RECIST v1.1 as Assessed by the Investigator |
26.2 | — |
| SECONDARY Duration of Response (DOR) as Assessed by the IRC and the Investigator |
6.341; 6.735 | — |
| SECONDARY Progression-Free Survival (PFS) as Assessed by the IRC and the Investigator |
3.811; 3.811 | — |
| SECONDARY Disease Control Rate (DCR) as Assessed by the IRC and the Investigator |
54.4; 59.2 | — |
| SECONDARY Time to Response as Assessed by the IRC and the Investigator |
1.807; 1.807 | — |
| SECONDARY Confirmed Intracranial Objective Response Rate (iORR) in Participants With Brain Metastases at Baseline, as Assessed by the IRC |
14.5 | — |
| SECONDARY Duration of Intracranial Response in Participants With Brain Metastases at Baseline, as Assessed by the IRC |
NA | — |
| SECONDARY Intracranial Progression-Free Survival (iPFS) in Participants With Brain Metastases at Baseline, as Assessed by the IRC |
5.224 | — |
| SECONDARY Overall Survival (OS) |
21.290 | — |
| SECONDARY Number of Participants With One or More Treatment-emergent Adverse Event (TEAE) |
103; 12 | — |
| SECONDARY Number of Participants With Improvement in Health-Related Quality of Life (HRQOL) Based on European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score |
52; 55; 53; 36; 47; 53 | — |
| SECONDARY Number of Participants With Improvement of HRQOL Based on EORTC QLQ- Lung Cancer (LC) 13 |
61; 45; 37; 4; 6; 4 | — |
Summary
The primary purpose of this study is to determine the efficacy of brigatinib by confirmed objective response rate (ORR) by response evaluation criteria in solid tumors (Response Evaluation Criteria in Solid Tumors [RECIST]), in participants with ALK+ locally advanced or metastatic NSCLC whose disease has progressed on therapy with alectinib or ceritinib.
Eligibility Criteria
Inclusion Criteria
- Have histologically or cytologically confirmed stage IIIB (locally advanced or recurrent and not a participant for curative therapy) or stage IV non-small-cell lung cancer (NSCLC).
- Must meet both of the following 2 criteria:
- Have documentation of anaplastic lymphoma kinase (ALK) rearrangement by a positive result from any laboratory test® approved by the food and drug administration (FDA) or Have documented ALK rearrangement by a different test (non-FDA-approved local lab tests) and have provided tumor sample to the central laboratory. (Note: Central laboratory ALK rearrangement testing results are not required to be obtained before randomization.)
- Had been on any one of the ALK tyrosine kinase inhibitor (TKIs) (alectinib, ceritinib, crizotinib) for at least 12 weeks before progression.
- Had progressive disease (PD) while on alectinib or ceritinib
- Had alectinib or ceritinib as the most recent ALK inhibitor therapy.
- Have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) version 1.1 as assessed by the investigator.
- Had recovered from toxicities related to prior anticancer therapy to national cancer institute common terminology criteria for adverse events (NCI CTCAE), version 4.03, Grade 1 are allowed if deemed irreversible.) and have adequate major organ functions.
- Have a life expectancy of ≥3 months.
Exclusion Criteria
- Had received any prior ALK-targeted TKI other than crizotinib, alectinib, or ceritinib.
- Had received both alectinib and ceritinib.
- Had previously received more than 3 regimens of systemic anticancer therapy for locally advanced or metastatic disease.
- Had symptomatic brain metastasis (parenchymal or leptomeningeal). Participants with asymptomatic brain metastasis or who have stable symptoms that did not require an increased dose of corticosteroids to control symptoms in the past 7 days before the first dose of brigatinib may be enrolled.
- Had current spinal cord compression (symptomatic or asymptomatic and detected by radiographic imaging). Participants with leptomeningeal disease and without cord compression are allowed.
- Had a cerebrovascular accident or transient ischemic attack within 6 months before first dose of brigatinib.
- Had an ongoing or active infection, including, but not limited to, the requirement for intravenous antibiotics.
- Had malabsorption syndrome or other gastrointestinal (GI) illness that could affect oral absorption of brigatinib.
Data sourced from ClinicalTrials.gov (NCT03535740). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.